639 related articles for article (PubMed ID: 22031357)
1. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
3. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
4. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
5. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
6. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.
Subramaniam K; D'Rozario J; Pavli P
J Gastroenterol Hepatol; 2013 Jan; 28(1):24-30. PubMed ID: 23094824
[TBL] [Abstract][Full Text] [Related]
7. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
8. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
[TBL] [Abstract][Full Text] [Related]
9. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
10. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
11. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
13. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study.
Vos AC; Bakkal N; Minnee RC; Casparie MK; de Jong DJ; Dijkstra G; Stokkers P; van Bodegraven AA; Pierik M; van der Woude CJ; Oldenburg B; Hommes DW;
Inflamm Bowel Dis; 2011 Sep; 17(9):1837-45. PubMed ID: 21830262
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
16. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic features of Crohn's disease associated with failure of medical treatment.
Moran GW; Dubeau MF; Kaplan GG; Yang H; Seow CH; Fedorak RN; Dieleman LA; Barkema HW; Ghosh S; Panaccione R;
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
[TBL] [Abstract][Full Text] [Related]
19. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
Stobaugh DJ; Deepak P
Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
[TBL] [Abstract][Full Text] [Related]
20. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]